Latest News about TEVA
Recent news which mentions TEVA
Why Teva Pharmaceutical Stock Is Jumping Today
November 02, 2021
From Motley Fool
California Judge Rules For Drugmakers In Major Opioid Litigation
November 02, 2021
From Benzinga
24 Stocks Moving in Tuesday's Pre-Market Session
November 02, 2021
From Benzinga
Teva Reports Encouraging Data From Late-Stage Schizophrenia Trial
November 01, 2021
Tickers
TEVA
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 28, 2021
October 28, 2021
From Benzinga
Tickers
TEVA
From Motley Fool
Looking Into Teva Pharmaceutical Indus's Return On Capital Employed
October 27, 2021
Tickers
TEVA
From Benzinga
Teva Q3 Earnings Fall Short Of Expectations; Reaffirms FY21 Guidance
October 27, 2021
Tickers
TEVA
From Benzinga
Earnings Scheduled For October 27, 2021
October 27, 2021
From Benzinga
Xenon: Heading Toward Phase III With Strong Momentum
October 26, 2021
From InvestorPlace
Why Humana Is Suing Biogen
October 09, 2021
From Motley Fool
10 Health Care Stocks With Unusual Options Alerts In Today's Session
October 08, 2021
From Benzinga
5 Warren Buffett Stocks to Buy Hand Over Fist for the Fourth Quarter
October 08, 2021
From Motley Fool
From Benzinga
Teva Stops Production At U.S. Plant After FDA Concerns: Reports
October 04, 2021
Tickers
TEVA
From Benzinga
Investing in Pharma Stocks? Watch for These 2 Red Flags
October 04, 2021
From Motley Fool
3 Biotech Stocks With Huge Catalysts This Fall
September 29, 2021
From Motley Fool
Why Teva Pharmaceutical Industries Shot Higher Today
September 28, 2021
Tickers
TEVA
From Motley Fool
Is It Time to Buy Warren Buffett's Lowest-Priced Stock?
September 22, 2021
From Motley Fool
Built to Deconstruct: Creating an Up-Cyclable Playground
September 21, 2021
Is Now the Time to Ditch Pharma Stocks?
September 21, 2021
From Motley Fool
3 Smartest Big Pharma Stocks to Buy in September
September 11, 2021
From Motley Fool
3 Discounted Buffett Stocks to Buy Hand Over Fist in September
September 08, 2021
From Motley Fool
The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering
September 01, 2021
From Benzinga
Teva-MedinCell's Schizophrenia Treatment Candidate Under FDA Review
September 01, 2021
Tickers
TEVA
From Benzinga
From Benzinga
Christina Applegate reveals she has MS, which costs patients more than $4 million over their lifetimes
August 10, 2021
From MarketWatch
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.